Innovations in serum and urine markers in prostate cancer: Current European research in the P-Mark project

European Urology

Volumn 48, Issue 6, 2005, Pages 1031-1041

  Van Gils, M P M Q ^a   Stenman, U H ^a   Schalken, J A ^a   Schroder F H ^a   Luider, T M ^a   Lilja, H ^a   Bjartell, A ^a   Hamdy, F C ^a   Pettersson, K S I ^a   Bischoff, R ^a   Takalo, H ^a   Nilsson, O ^a   Mulders, P F A ^a   Bangma, C H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Biological; Diagnosis; Prognosis; Prostatic neoplasms; Serum; Tumor markers; Urine

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANDROGEN; ANDROGEN RECEPTOR; APOLIPOPROTEIN A2; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 6; CALGRANULIN; CAVEOLIN 1; CYTOCHROME P450; GELATINASE A; GELATINASE B; GLUTATHIONE TRANSFERASE; KALLIKREIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROGASTRIN RELEASING PEPTIDE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SIALOPROTEIN; SOMATOMEDIN C; TESTOSTERONE; TUMOR MARKER; VASCULOTROPIN;

ANDROGEN METABOLISM; BLOOD ANALYSIS; BONE METABOLISM; CANCER CLASSIFICATION; CANCER GROWTH; CANCER RESEARCH; CANCER RISK; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DISEASE MARKER; EARLY DIAGNOSIS; EUROPE; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MASS SPECTROMETRY; MULTIGENE FAMILY; OSSIFICATION; OSTEOLYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN FAMILY; PROTEIN URINE LEVEL; RECEPTOR GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; URINALYSIS; VALIDATION PROCESS;

BONE MORPHOGENETIC PROTEINS; HUMANS; MALE; MASS SPECTROMETRY; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TISSUE KALLIKREINS; TUMOR MARKERS, BIOLOGICAL;

EID: 27844585571     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.06.009     Document Type: Review

References (59)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No. 5. version 2 0, IARC Press, Lyon 2004.
2. E. Kikuchi, J. Nakashima, M. Ishibashi, T. Ohigashi, H. Asakura, and M. Tachibana Prostate specific antigen adjusted for transition zone volume: the most powerful method for detecting prostate carcinoma Cancer 89 2000 842 849
3. G.M. Cannon Jr., P.C. Walsh, A.W. Partin, and C.R. Pound Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer Urology 62 Suppl 1 2003 2 8
4. W.J. Catalona, D.S. Smith, R.L. Wolfert, T.J. Wang, H.G. Rittenhouse, and T.L. Ratliff Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening JAMA 274 1995 1214 1220
5. P. Finne, R. Finne, C. Bangma, J. Hugosson, M. Hakama, and A. Auvinen Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening Int J Cancer 111 2004 310 315
6. P.C. Southwick, W.J. Catalona, A.W. Partin, K.M. Slawin, M.K. Brawer, and R.C. Flanigan Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial J Urol 162 1999 1346 1351
7. L. Zhu, J. Leinonen, W.M. Zhang, P. Finne, and U.H. Stenman Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1-antichymotrypsin complex together with free or total PSA Clin Chem 49 2003 97 103
8. W.M. Zhang, P. Finne, J. Leinonen, J. Salo, and U.H. Stenman Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer Urology 56 2000 267 272
9. J.K. Parsons, M.K. Brawer, C.D. Cheli, A.W. Partin, and R. Djavan Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA BJU Int 94 2004 47 50
10. S.D. Mikolajczyk, W.J. Catalona, C.L. Evans, H.J. Linton, L.S. Millar, and K.M. Marker Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer Clin Chem 50 2004 1017 1025
11. T. Steuber, P. Nurmikko, A. Haese, K. Pettersson, M. Graefen, and P. Hammerer Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen J Urol 168 2002 1917 1922
12. A. Haese, M. Graefen, T. Steuber, C. Becker, J. Noldus, and A. Erbersdobler Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies J Urol 170 2003 2269 2273
13. C.H. Bangma, M.F. Wildhagen, G. Yurdakul, F.H. Schroder, and B.G. Blijenberg The value of (-7, 5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer BJU Int 93 2004 720 724
14. M.H. Weinstein, A.W. Partin, R.W. Veltri, and J.I. Epstein Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy Hum Pathol 27 1996 683 687
15. J.V. Tricoli, M. Schoenfeldt, and B.A. Conley Detection of prostate cancer and predicting progression: current and future diagnostic markers Clin Cancer Res 10 2004 3943 3953
16. N. Kamiya, K. Akakura, H. Suzuki, S. Isshiki, A. Komiya, and T. Ueda Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy Eur Urol 44 2003 309 314
17. T.R. Rebbeck, J.M. Jaffe, A.H. Walker, A.J. Wein, and S.B. Malkowicz Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 J Natl Cancer Inst 90 1998 1225 1229
18. S.J. Plummer, D.V. Conti, P.L. Paris, A.P. Curran, G. Casey, and J.S. Witte CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer Cancer Epidemiol Biomarkers Prev 12 2003 928 932
19. R.H. van Schaik, S.N. de Wildt, N.M. van Iperen, A.G. Uitterlinden, J.N. van den Anker, and J. Lindemans CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians Clin Chem 46 2000 1834 1836
20. R.H. van Schaik, I.P. van der Heiden, J.N. van den Anker, and J. Lindemans CYP3A5 variant allele frequencies in Dutch Caucasians Clin Chem 48 2002 1668 1671
21. B.L. Chang, S.L. Zheng, S.D. Isaacs, A. Turner, G.A. Hawkins, and K.E. Wiley Polymorphisms in the CYP1A1 gene are associated with prostate cancer risk Int J Cancer 106 2003 375 378
22. B.L. Chang, S.L. Zheng, S.D. Isaacs, A. Turner, G.A. Hawkins, and K.E. Wiley Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer Br J Cancer 89 2003 1524 1529
23. C. Goessl, M. Muller, R. Heicappell, H. Krause, B. Straub, and M. Schrader DNA-based detection of prostate cancer in urine after prostatic massage Urology 58 2001 335 338
24. M.J. Bussemakers, A. van Bokhoven, G.W. Verhaegh, F.P. Smit, H.F. Karthaus, and J.A. Schalken DD3: a new prostate-specific gene, highly overexpressed in prostate cancer Cancer Res 59 1999 5975 5979
25. J.B. de Kok, G.W. Verhaegh, R.W. Roelofs, D. Hessels, L.A. Kiemeney, and T.W. Aalders DD3(PCA3), a very sensitive and specific marker to detect prostate tumors Cancer Res 62 2002 2695 2698
26. D. Hessels, J.M. Klein Gunnewiek, I. van Oort, H.F. Karthaus, G.J. van Leenders, and B. van Balken DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer Eur Urol 44 2003 8 15
27. Z. Xiao, B.L. Adam, L.H. Cazares, M.A. Clements, J.W. Davis, and P.F. Schellhammer Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease Cancer Res 61 2001 6029 6033
28. K. Jung, M. Lein, C. Stephan, K. Von Hosslin, A. Semjonow, and P. Sinha Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications Int J Cancer 111 2004 783 791
29. C. De la Piedra, N.A. Castro-Errecaborde, M.L. Traba, C. Mendez-Davila, C. Garcia-Moreno, and L. Rodriguez de Acuña Bone remodeling markers in the detection of bone metastases in prostate cancer Clin Chim Acta 331 2003 45 53
30. M. Noguchi, and S. Noda Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer J Urol 166 2001 1106 1110
31. L.F. Wymenga, K. Groenier, J. Schuurman, J.H. Boomsma, R.O. Elferink, and H.J. Mensink Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis BJU Int 88 2001 231 235
32. G. De Pinieux, T. Flam, M. Zerbib, P. Taupin, A. Bellahcene, and D. Waltregny Bone sialoprotein, bone morphogenetic protein 6 and thymidine phosphorylase expression in localized human prostatic adenocarcinoma as predictors of clinical outcome: a clinicopathological and immunohistochemical study of 43 cases J Urol 166 2001 1924 1930
33. P. Autzen, C.N. Robson, A. Bjartell, A.J. Malcolm, M.I. Johnson, and D.E. Neal Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies Br J Cancer 78 1998 1219 1223
34. C.L. Eaton, J.M. Wells, I. Holen, P.I. Croucher, and F.C. Hamdy Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer Prostate 59 2004 304 310
35. R. Herwig, A. Pelzer, W. Horninger, P. Rehder, H. Klocker, and R. Ramoner Measurement of intracellular versus extracellular prostate-specific antigen levels in peripheral macrophages: a new approach to noninvasive diagnosis of prostate cancer Clin Prostate Cancer 3 2004 184 188
36. R. Herwig, W. Horninger, P. Rehder, H. Klocker, R. Ramoner, and M. Thurnher Ability of PSA-positive circulating macrophages to detect prostate cancer Prostate 62 2005 290 298
37. T. Nakamura, A. Scorilas, C. Stephan, K. Jung, A.R. Soosaipillai, and E.P. Diamandis The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia Cancer Res 63 2003 6543 6546
38. M. Yashi, A. Nukui, S. Kurokawa, M. Ochi, S. Ishikawa, and K. Goto Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer Prostate 56 2003 305 312
39. M. Shimbo, H. Suzuki, N. Kamiya, T. Imamoto, A. Komiya, and T. Ueda CAG Polymorphic Repeat Length in Androgen Receptor Gene Combined with Pretreatment Serum Testosterone Level as Prognostic Factor in Patients with Metastatic Prostate Cancer Eur Urol 47 2005 557 563
40. T. Kumazawa, N. Tsuchiya, L. Wang, K. Sato, T. Kamoto, and O. Ogawa Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer Int J Cancer 110 2004 140 144
41. C.C. Chiou, P.Y. Chang, E.C. Chan, T.L. Wu, K.C. Tsao, and J.T. Wu Urinary 8-hydroxydeoxyguanosine and its analogs as DNA marker of oxidative stress: development of an ELISA and measurement in both bladder and prostate cancers Clin Chim Acta 334 2003 87 94
42. M. Tanaka, T. Tanaka, S. Matsuzaki, Y. Seto, T. Matsuda, and K. Komori Rapid and quantitative detection of human septin family Bradeion as a practical diagnostic method of colorectal and urologic cancers Med Sci Monit 9 2003 MT61 MT68
43. N.V. Lyubimova, M.V. Pashkov, S.A. Tyulyandin, V.E. Gol'dberg, and N.E. Kushlinskii Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer Bull Exp Biol Med 138 2004 77 79
44. K. Jung, C. Stephan, A. Semjonow, M. Lein, D. Schnorr, and S.A. Loening Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer J Urol 170 2003 2302 2305
45. M. Kohli, V. Kaushal, H.J. Spencer, and P. Mehta Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer Urology 61 2003 765 769
46. C.G. Sauer, A. Kappeler, M. Spath, J.J. Kaden, M.S. Michel, and D. Mayer Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients Virchows Arch 444 2004 518 526
47. J.C. Massengill, L. Sun, J.W. Moul, H. Wu, D.G. McLeod, and C. Amling Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy J Urol 169 2003 1670 1675
48. K. Woodson, J.A. Tangrea, M. Pollak, T.D. Copeland, P.R. Taylor, and J. Virtamo Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men Cancer Res 63 2003 3991 3994
49. S.A. Tahir, C. Ren, T.L. Timme, Y. Gdor, R. Hoogeveen, and J.D. Morrisett Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer Clin Cancer Res 9 2003 3653 3659
50. G. Malik, M.D. Ward, S.K. Gupta, M.W. Trosset, W.E. Grizzle, and B.L. Adam Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer Clin Cancer Res 11 2005 1073 1085
51. J.J. Hlavaty, A.W. Partin, M.J. Shue, L.A. Mangold, J. Derby, and T. Javier Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer Urology 61 2003 1261 1265
52. I. Rehman, A.R. Azzouzi, J.W. Catto, S. Allen, S.S. Cross, and K. Feeley Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study Urology 64 2004 1238 1243
53. F.H. Schroder, L.J. Denis, M. Roobol, V. Nelen, A. Auvinen, and T. Tammela The story of the European Randomized Study of Screening for Prostate Cancer BJU Int 92 Suppl 2 2003 1 13
54. J. Donovan, F. Hamdy, D. Neal, T. Peters, S. Oliver, and L. Brindle Prostate Testing for Cancer and Treatment (ProtecT) feasibility study Health Technol Assess 7 2003 1 88
55. M. Karas, and F. Hillenkamp Laser desorption ionization of proteins with molecular masses exceeding 10,000 daltons Anal Chem 60 1988 2299 2301
56. J.B. Fenn, M. Mann, C.K. Meng, S.F. Wong, and C.M. Whitehouse Electrospray ionization for mass spectrometry of large biomolecules Science 246 1989 64 71
57. M.B. Comisarow, and A.G. Marshall Fourier transform ion cyclotron resonance spectroscopy Chem Phys Lett 25 1974 282 283
58. T.W. Hutchens, and T.T. Yip New desorption strategies for the mass spectrometric analysis of macromolecules Rapid Commun Mass Spectrom 7 1993 576 580
59. E.F. Petricoin III, D.K. Ornstein, C.P. Paweletz, A. Ardekani, P.S. Hackett, and B.A. Hitt Serum proteomic patterns for detection of prostate cancer J Natl Cancer Inst 94 2002 1576 1578